April 2023 in “Journal of Investigative Dermatology” This study found that intradermal injection of a specially designed RNA molecule, cp-asiAR, successfully reduced androgen receptor levels and promoted hair growth in a mouse model of androgenetic alopecia, while also improving hair follicle characteristics in ex vivo human scalp tissues without significant toxicity.
In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.
November 2022 in “Molecular Pharmaceutics” This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.
September 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” This study found that a chemically modified small-interfering RNA candidate, AR-27 E-Chol, effectively stimulated hair regrowth and reduced androgen receptor gene expression in a mouse model of androgenetic alopecia, indicating its potential as a novel therapeutic approach.
September 2025 in “Journal of Medicinal Chemistry” This study evaluated a chemically modified siRNA, AR-27 E-Chol, which effectively promoted hair regrowth and reduced androgen receptor gene expression in a DHT-induced mouse model of androgenetic alopecia, suggesting its potential as a novel therapeutic candidate.
